Last reviewed · How we verify
NCT05590221
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Phase 2 trial testing Relmacabtagene Autoleucel in B-cell Lymphoma in 20 participants. Status unknown.
10 February 2024
Quick facts
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 3 January 2023 |
| Primary completion | 10 February 2024 |
| Estimated completion | 10 December 2024 |
| Sites | 4 locations across China |
Drugs / interventions tested
- Relmacabtagene Autoleucel
- Fludarabine (FLUDARABINE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- B-cell Lymphoma — all drugs for B-cell Lymphoma →
Sponsor
Peking University Cancer Hospital & Institute
Who can join
18 and older, any sex, with B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05590221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Relmacabtagene Autoleucel
Trials testing the same drug.
- NCT06142188 — Relmacabtagene Autoleucel in Hematologic Malignancies · not yet recruiting
- NCT06093841 — Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · Phase 2 · active not recruiting
- NCT06142175 — Relmacabtagene Autoleucel in Patients With LBCL · unknown
Other recruiting trials for B-cell Lymphoma
Currently open trials in the same condition.
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT06758713 — Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies · Phase 1 · recruiting
- NCT06820268 — A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies · Phase 1 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06744075 — Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma · NA · active not recruiting
Other Peking University Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
- NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05590221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
- Last refreshed: 8 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05590221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing